cas 1560-11-8|| where to buy cyclopent-1-ene-1-carboxylic acid

Nom du produit:cyclopent-1-ene-1-carboxylic acid

IUPAC Name:cyclopent-1-ene-1-carboxylic acid

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM202326-10g	in stock	ɅŴƱ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1560-11-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1560-11-8; Formule moléculaire:C6H8O2; Point de fusion:-; Code SMILES:O=C(C1=CCCC1)O; Densité:

: Numéro de catalogue:CM202326; Poids moléculaire:112.13; Point d'ébullition:210°C at 760 mmHg; N° Mdl:MFCD00001396; Stockage:Store at 2-8°C.

: Cyclopentanes; Cyclopentane is a cycloalkane, an organic compound with a molecular formula of C5H10, a colorless and transparent liquid, insoluble in water, soluble in most organic solvents such as ethanol, ether, benzene, carbon tetrachloride, acetone, etc. It is mainly used as a solvent and chromatographic reference materials.; Cyclopentanes,where to buy Cyclopentanes; Cyclopentanes; Cyclopentane (also called C pentane) is a highly flammable alicyclic hydrocarbon with chemical formula C5H10 and CAS number 287-92-3, consisting of a ring of five carbon atoms each bonded with two hydrogen atoms above and below the plane. It occurs as a colorless liquid with a petrol-like odor.

: Ribociclib; FDA has approved Novartis Kisqali(ribociclib) to reduce risk of recurrence in people with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-) early breast cancer (EBC).
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Beyond today’s FDA approval of Kisqali for EBC patients in the US, regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.